As Novartis newcomer and former Pfizer exec Liz Bennett takes the helm as the company’s CEO for Oncology, she sat down with Scrip for an interview outlining her plans and strategies to take the company forward.
Read about her insights into the future of Novartis Oncology, including navigating the loss of patent on blockbuster Gleevec, getting relatively new CAR-T therapy drug Kymriah and CDK4/6 inhibitor Kisqali (ribociclib) off to the races, and her experience adjusting to a new company culture, in this exclusive interview with Scrip.
Read about her insights into the future of Novartis Oncology, including navigating the loss of patent on blockbuster Gleevec, getting relatively new CAR-T therapy drug Kymriah and CDK4/6 inhibitor Kisqali (ribociclib) off to the races, and her experience adjusting to a new company culture, in this exclusive interview with Scrip.
